Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBX7 | O95931 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23144847 | 0.90 | CBX7 (0.83) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL23178209 | 0.89 | CBX7 (1.00) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL23145132 | 0.86 | CBX7 (0.64) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL29822359 | 0.82 | CBX7 (0.86) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL23144862 | 0.82 | CBX7 (0.86) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL12084205 | 0.81 | CBX7 (0.74) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL24760067 | 0.81 | CBX7 (0.73) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL23177970 | 0.80 | CBX7 (0.81) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL23144892 | 0.80 | CBX7 (0.81) | CBX7HTTPOLBSLC2A1NPSR1 | |
| SCHEMBL23177924 | 0.80 | CBX7 (0.72) | CBX7HTTPOLBSLC2A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-18 | — | — | US | disclosed |
| US-20220402880-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220402880-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-22 | — | — | US | disclosed |
| EP-4034250-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | Icahn School of Medicine at Mount Sinai (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021061801-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | ICAHN SCHOOL OF MEDICINE AT MT. SINAI (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021061801-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | ICAHN SCHOOL OF MEDICINE AT MT. SINAI (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | CBX2, CBX3, CBX6 | CBX7 4/4885HTT 4261/4885POLB 3961/4885 |
| US-20220402880-A1 | BICYCLIC INHIBITORS OF CBX CHROMODOMAINS | CBX2, CBX3, CBX7 | CBX7 3/4885HTT 3837/4885POLB 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.